Related Experiment Video
Updated: Jun 13, 2026
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Fibronectin plasma levels in gynecological cancers
I E Grammatikakis1, D C Botsis, O V Grigoriou
12nd Department of Obstetrics and Gynecology, University Hospital Aretaieion, University of Athens, Athens, Greece. gramjh@yahoo.gr
Summary
Fibronectin (FBN) plasma levels were significantly elevated in gynecological cancer patients compared to healthy women. Higher FBN levels were observed in breast and cervical cancers, suggesting FBN as a potential biomarker.
Area of Science:
- Oncology
- Biochemistry
Background:
- Fibronectin (FBN) plays a role in cancer cell motility and migration.
- Investigating FBN plasma levels can offer insights into gynecological cancer progression.
Purpose of the Study:
- To determine and compare plasma fibronectin (FBN) levels in women with gynecological cancers versus healthy controls.
- To explore the potential of FBN as a biomarker for gynecological malignancies.
Main Methods:
- A study involving 100 women with gynecological cancers (cervix, ovary, endometrium, breast) and 100 healthy women.
- Fibronectin (FBN) plasma levels were quantified using the radial immunodiffusion method between 1998 and 2003.
Main Results:
- Patients with gynecological cancers exhibited significantly higher median plasma FBN levels (258.4 mg/l) compared to the control group (213 mg/l).
- Elevated FBN levels were particularly noted in breast and cervical cancers relative to ovarian and endometrial cancers.
- A statistically significant "tail" of high plasma FBN levels (>400 mg/l) was observed in the patient group.
Conclusions:
- Plasma fibronectin (FBN) levels are significantly elevated in the overall group of gynecological cancer patients.
- The increase in FBN was not statistically significant in the subgroup of endometrial and ovarian cancers.
- Further research with larger patient cohorts is recommended to validate FBN as a reliable biomarker for gynecological cancers.
